It can also be very difficult to know precisely when patients stop trial medication, particularly if they die suddenly. This is, however, less of a problem if the analysis is done blind to treatment allocation, which it was in the CATS study.
However, the efficacy analysis in CATS demonstrated a 30-2010 reduction (95%" confidence interval 7.5%0483% reduction) in the relative risk of the composite "end-point" of stroke/myocardial infarction/vascular death attributable to ticlopidine. Using such a composite end-point is justified since an antithrombotic drug is likely to influence favourably all three components, unlikely to influence nonvascular death which in fact was the case, and, by providing a larger number of events than its individual constitutents, increases the power of the analysis. The risk reduction for fatal and non-fatal recurrent stroke was similar at 33-5%.
If all events in all eligible patients were counted, the relative risk reduction for stroke/myocardial infarction/ vascular death dropped to 2333%, and for fatal and nonfatal stroke to 20 5%. The former was only just statistically significant and the 95% confidence interval was wide (1 0 to 40-5% risk reduction). This analysis was based on the more rigorous "intention-to-treat" principle in which every event in every randomised patient is counted up to the scheduled end of the trial whether the patient is taking trial medication or not. This is much preferred because, although less sensitive to a treatment effect, it is potentially less biased than an efficacy analysis. Thus, it seems that ticlopidine almost certainly does reduce the risk of serious vascular events if taken for a year or two after a major ischaemic stroke but it is not certain how big that effect is; it could be less than a 10% relative risk reduction or it could be almost a 5000 risk reduction. But what about the side effects? Clearly for some people ticlopidine is a mildly unpleasant drug to take since 12% of the patients stopped taking it compared with 3% stopping placebo. The most common side effects were diarrhoea and skin rash but the most worrying was the occasional patient with neutropenia which implies that in routine clinical practice blood monitoring will be necessary for a few months after starting ticlopidine. This will certainly increase the cost of the treatment both directly and indirectly.
There is corroborative evidence supporting the efficacy of ticlopidine. In patients with intermittent claudication, a meta-analysis of trials of ticlopidine versus placebo has already suggested a therapeutic effect of ticlopidine on Kingdom, at least, be regarded as rather an unnecessarily high dose of aspirin, 1300 mg a day). Once again neutropenia was found to occur in a few cases and was severe enough to make it necessary for frequent blood monitoring in patients taking ticlopidine in routine clinical practice. Strangely, the most significant difference between ticlopidine and aspirin was in non-vascular death in favour of the former drug, presumably a chance effect because it was unexpected and applied as much to noncancer as cancer deaths. This also explains why the authors' preferred analysis based on stroke and/or death gave more promising results than my own based on stroke and/or vascular death which, if ticlopidine really has no effect on non-vascular death, is a more relevant "end-point" for assessing an antithrombotic drug.
It seems therefore that ticlopidine is not definitely more effective than aspirin in preventing serious vascular events in TIA and mild ischaemic stroke patients, and it is more toxic and expensive. Thus, there is no logical reason to start treatment with ticlopidine in vascular at-risk patients (that is, after TIA and ischaemic strokes). This raises a further question.
Which longterm antithrombotic treatment should be recommended if 300 mg aspirin daily cannot be used because of previous or current gastric intolerance? All the above arguments do presuppose that the effective- 
mild ischaemic strokes (as addressed by the APT collaboration and TASS trial) as after more major ischaemic strokes (as addressed by the CATS trial). In other words, that it is biologically sensible, and therefore legitimate, to compare the effect of aspirin in TIA or mild ischaemic stroke patients with the effect of ticlopidine in major ischaemic stroke patients. Unfortunately, there have been no large trials of aspirin alone in major ischaemic stroke, and none at all of the direct comparison of aspirin against ticlopidine. Since it is unlikely that randomised comparisons of aspirin with ticlopidine in major ischaemic stroke patients will ever be done, we will have to make do with inferences from the data we do have.
It seems to me inherently unlikely that there is any qualitative difference between TIA and mild ischaemic stroke patients (indeed there is now evidence that this is true)5, nor any inherent reason why these two groups should be qualitatively any different from severe ischaemic stroke. There is similar underlying arterial pathology although the clinical effects of atheroma, thrombosis, and embolism are quantitatively different, hence the different clinical presentations of TIA and stroke. Also, as far as one can tell, the subsequent risk of serious vascular events is not very different after transient ischaemic attacks, mild ischaemic strokes, and more major ischaemic strokes; any differences there are between patients are probably more likely to be due to prognostic variables such as age, blood pressure, extent of arterial disease. Therefore, it is rather implausible that the relative risk reduction attributable to antiplatelet agents is going to be any different whether the patient presents with a TIA or a mild or major ischaemic stroke.
The alternative argument is to refuse to generalise from the APT and TASS trial, and conclude that aspirin should only be used for patients who recover from a cerebrovascular event, while ticlopidine should only be used in those who do not recover on the basis of CATS. However, it seems so implausible that the mere fact of recovery determines a clinically important difference between two antiplatelet drugs, that I prefer to generalise the results from the "TIA" trials to my individual stroke patients as well as TIA patients, and from the CATS trial in stroke to my individual "TIA" as well as stroke patients.
Therefore, if a TIA or ischaemic stroke patient of any grade of severity cannot take 300 mg aspirin daily one might conclude from the TASS trial that he should take ticlopidine. But, it is worth reconsidering the APT results.' This overview did suggest that sulphinpyrazone reduced the odds of stroke/myocardial infarction/vascular death by 17% (with a very wide 95% confidence interval from 1-33% reduction) but it was not conclusively more (or less) effective than aspirin alone. However, unlike ticlopidine, at least sulphinpyrazone is currently available in the United Kingdom, thus my recommendation would be that if aspirin cannot be used (even enteric coated in as low a dose as 300 mg daily which is the lowest which definitely works in this situation) one can do one of two things; either use a lower dose still (150 mg or even 75 mg daily) based on the pharmacological evidence that it should be as effective as the higher dose and backed up by some, but not many clinical trials, or, use sulphinpyrazone 200 mg four times daily based on somewhat better clinical trial evidence but still short of complete certainty.
This conclusion will certainly need refining from the next cycle ofthe APT which should help clarify the place of ticlopidine in the longterm management of TIA and ischaemic stroke patients, and which will also direct priorities for future randomised clinical trials of ticlopidine. 
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